Beam Therapeutics
BEAM
60 hedge funds and large institutions have $484M invested in Beam Therapeutics in 2020 Q1 according to their latest regulatory filings, with 60 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
54.15% more ownership
Funds ownership: 0% → 54.15% (+54%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$152M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$73M |
| 3 |
Temasek Holdings
Singapore
|
+$72.9M |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$64.5M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
+$35.4M |
Top Sellers
BEAM Hedge Fund Activity: Q1 2020 in Review
60 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q1 2020, worth a combined $484M.
Buyers outnumbered sellers: 60 funds opened new BEAM positions and 0 closed out — a net gain of 60 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $152M.
- 60 institutional investors held Beam Therapeutics (BEAM) as of Q1 2020, up from 0 in Q4 2019.
- Funds reported $484M of Beam Therapeutics stock for Q1 2020.
- 60 funds opened new Beam Therapeutics positions in Q1 2020 and 0 closed out, a net change of +60 holders.
- The largest Beam Therapeutics buyer in Q1 2020 was Fidelity Investments, an estimated $152M added.
Based on aggregated 13F filings for Q1 2020.